TY  - JOUR
AU  - Facey, Karen M
AU  - Espin, Jaime
AU  - Kent, Emma
AU  - Link, Angel
AU  - Nicod, Elena
AU  - O'Leary, Aisling
AU  - Xoxi, Entela
AU  - van de Vijver, Inneke
AU  - Zaremba, Anna
AU  - Benisheva, Tatyana
AU  - Vagoras, Andrius
AU  - Upadhyaya, Sheela
PY  - 2021
DO  - 10.1007/s40273-021-01050-5
UR  - http://hdl.handle.net/10668/18169
T2  - PharmacoEconomics
AB  - Enthusiasm for the use of outcomes-based managed entry agreements (OBMEAs) to manage uncertainties apparent at the time of appraisal/pricing and reimbursement of new medicines has waned over the past decade, as challenges in establishment,...
LA  - en
PB  - SpringerNature
KW  - Outcomes-based managed entry agreements (OBMEAs)
KW  - Rare diseases
KW  - Reimbursement frameworks
KW  - Health technology assessment (HTA)
KW  - Data collection systems
KW  - Coverage with evidence development (CED)
KW  - Costs and Cost Analysis
KW  - Humans
KW  - Oligonucleotides
KW  - Rare Diseases
KW  - Receptors, Antigen, T-Cell
KW  - Technology Assessment, Biomedical
TI  - Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.
TY  - research article
VL  - 39
ER  -